Laboratory and Clinical Settings of Heavy/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma.
free light chain
heavy/light chain
monoclonal component
multiple myeloma
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
27 Apr 2023
27 Apr 2023
Historique:
received:
30
03
2023
revised:
19
04
2023
accepted:
25
04
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
The antibody-related immune response is mediated by immunoglobulins (Igs), soluble circulating glycoproteins produced by activated B cells that, upon the recognition of specific epitopes on pathogen surfaces, activate, proliferate, and differentiate into antibody-secreting plasma cells. Although the antibodies are effectors of the humoral immune adaptive response, their overproduction in response to a dysregulated proliferation of clonal plasma cell production in tumoral conditions (i.e., multiple myeloma), enriches the serum and urinary matrices, assuming the crucial role of biomarkers. Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the expansion and accumulation of clonally activated plasma cells in bone marrow, determining the release of high amounts of monoclonal component (MC) that can be detected as intact immunoglobulin (Ig), immunoglobulin fragments, or free light chains (FLCs). The importance of detecting biomarkers for the diagnosis, monitoring, and prognosis of diseases is highlighted by the international guidelines that recommend specific assays for the analysis of intact Igs and FLC. Moreover, a developed assay called Hevylite
Identifiants
pubmed: 37240913
pii: jpm13050743
doi: 10.3390/jpm13050743
pmc: PMC10220754
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Blood. 2006 Sep 1;108(5):1733-43
pubmed: 16705090
Neoplasma. 2015;62(5):827-32
pubmed: 26278155
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Clin Chem. 2015 Feb;61(2):360-7
pubmed: 25451866
N Engl J Med. 2018 Jan 18;378(3):241-249
pubmed: 29342381
Blood. 2014 May 29;123(22):3414-9
pubmed: 24733348
Blood Adv. 2019 Aug 13;3(15):2409-2423
pubmed: 31409583
Int J Lab Hematol. 2013 Oct;35(5):e10-2
pubmed: 23311353
Ann Clin Biochem. 2015 May;52(Pt 3):337-45
pubmed: 25468997
Blood. 2011 May 5;117(18):4701-5
pubmed: 21292778
Kidney Int. 2015 Apr;87(4):698-711
pubmed: 25607108
Eur Rev Med Pharmacol Sci. 2019 May;23(10):4293-4302
pubmed: 31173301
Clin Chem. 2001 Apr;47(4):673-80
pubmed: 11274017
Leuk Lymphoma. 2018 Mar;59(3):583-589
pubmed: 28697637
Biotechnol Appl Biochem. 2021 Apr;68(2):319-329
pubmed: 32333692
Expert Rev Mol Diagn. 2014 Jan;14(1):55-66
pubmed: 24308339
Biomed Res Int. 2014;2014:232546
pubmed: 25101266
Leuk Lymphoma. 2013 Sep;54(9):1898-907
pubmed: 23327290
Am J Hematol. 2016 Jul;91(7):719-34
pubmed: 27291302
Leukemia. 2013 Jan;27(1):213-9
pubmed: 22955329
Front Oncol. 2021 Mar 09;11:599532
pubmed: 33767978
J Clin Invest. 2012 Oct;122(10):3456-63
pubmed: 23023717
Lancet Oncol. 2016 Aug;17(8):1127-1136
pubmed: 27402145
Br J Haematol. 2014 Mar;164(5):752-5
pubmed: 24261626
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Clin Chem. 2015 Feb;61(2):317-8
pubmed: 25501934
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
Ann Hematol. 2021 Dec;100(12):2997-3005
pubmed: 34463804
Br J Haematol. 2016 Jul;174(1):81-7
pubmed: 27017948
Blood. 2018 Oct 4;132(14):1478-1485
pubmed: 30012636
Leukemia. 2018 Feb;32(2):376-382
pubmed: 28663581
Clin Chem Lab Med. 2018 Jun 27;56(7):1169-1175
pubmed: 29397379
Blood Cancer J. 2015 Apr 17;5:e306
pubmed: 25885426
Br J Haematol. 2016 Oct;175(1):77-86
pubmed: 27378193
Pathology. 2019 Aug;51(5):507-511
pubmed: 31253381
Clin Chim Acta. 2018 Apr;479:7-13
pubmed: 29324245
Leukemia. 2013 Jan;27(1):208-12
pubmed: 22781594
J Clin Oncol. 2005 Dec 20;23(36):9219-26
pubmed: 16275935
Cancer. 1975 Sep;36(3):842-54
pubmed: 1182674
Clin Chem. 2009 Sep;55(9):1646-55
pubmed: 19617289
QJM. 2007 Oct;100(10):635-40
pubmed: 17846059
Clin Chem Lab Med. 2016 Jun 1;54(6):1059-64
pubmed: 26812795
Hematology. 2016 Aug;21(7):392-8
pubmed: 26868131
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Am J Hematol. 2016 Mar;91(3):295-301
pubmed: 26662888
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Oncol Lett. 2016 Oct;12(4):2363-2370
pubmed: 27698801
Blood. 2006 Oct 15;108(8):2520-30
pubmed: 16794250
Exp Hematol Oncol. 2012 Apr 23;1(1):9
pubmed: 23211046
Transl Res. 2018 Nov;201:49-59
pubmed: 30301522
Leukemia. 2013 Jan;27(1):202-7
pubmed: 22699454
Nat Rev Nephrol. 2019 Feb;15(2):121
pubmed: 30568288
Br J Haematol. 2010 Feb;148(4):659-61
pubmed: 19863537
Blood. 2011 Jul 21;118(3):529-34
pubmed: 21482708
J Immunol Methods. 2020 Jan;476:112687
pubmed: 31669506
Diagnostics (Basel). 2021 Oct 30;11(11):
pubmed: 34829367
J Appl Lab Med. 2018 Mar 1;2(5):700-710
pubmed: 33636869